Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Hyperuricemia: A Marker of Severe Congestion and Disease Burden in Heart Failure
Session:
SESSÃO DE POSTERS 43 - INSUFICIÊNCIA CARDÍACA E COMORBILIDADES
Speaker:
José Luís Ferraro
Congress:
CPC 2025
Topic:
D. Heart Failure
Theme:
10. Chronic Heart Failure
Subtheme:
10.6 Chronic Heart Failure - Clinical
Session Type:
Cartazes
FP Number:
---
Authors:
José Luís Ferraro; Mauro Moreira; Ana Rodrigo Costa; Inês G. Campos; Rafaela G. Lopes; Joel Ponte Monteiro; Inês Almeida; Carla Almeida; Aurora Andrade
Abstract
<p style="text-align:justify"><span style="font-family:Verdana,Geneva,sans-serif"><span style="font-size:12pt"><strong>Background</strong>: Hyperuricemia has been linked to worse outcomes in heart failure (HF). The aim of this study was to evaluate the relationship between hyperuricemia and clinical characteristics and outcomes in hospitalized HF patients.</span></span></p> <p style="text-align:justify"><span style="font-family:Verdana,Geneva,sans-serif"><span style="font-size:12pt"><strong>Methods</strong>: A retrospective single-center analysis was conducted with 265 patients hospitalized for HF<span style="font-size:11.0pt"><span style="color:black"> throughout 2022</span></span>, divided into two groups: hyperuricemia (serum level at admission >7.5 mg/ml, n=137) and non-hyperuricemia (<7.5 mg/dl, n=105). A statistical analysis was performed to compare baseline characteristics and outcomes between groups. The combined endpoint included HF hospitalization, cardiovascular death, all-cause mortality, and unplanned hospital visits. A p-value of <0.05 was considered statistically significant. </span></span></p> <p style="text-align:justify"><span style="font-family:Verdana,Geneva,sans-serif"><span style="font-size:12pt"><strong>Results</strong>: 67.9% were male and mean age was 70.7 ± 12.4 years. The median follow-up period was 1.5 years. <span style="background-color:white"><span style="color:black">Cardiovascular risk factors were </span></span>prevalent. In the hyperuricemia group, 51 patients (37.2%) had ischemic etiology, compared to 48 patients (45.7%) (p =0.183). In the hyperuricemia group, 39 patients (28.5%) had valvular etiology, compared to 26 patients (24.8%) (p=0.519). Hyperuricemia group were predominantly classified in HF Profile B (89.8%) and Profile C (9.5%), with a very small proportion presenting cardiogenic shock. Non-hyperuricemia group were mostly classified in Profile B (93.3%) and 6.7% in Profile C. In patients with HFrEF, hyperuricemia group had a significantly lower LVEF (34.1% ± 14.37% vs. 38.1%, p=0.045). and were more likely to exhibit right ventricular dysfunction (39.7% vs. 26.7%, p=0.034). A weak positive correlation was found between serum uric acid levels and admission NT-proBNP levels (r = 0.273, p<0.001). Hyperuricemic patients required higher diuretic doses (67.9% vs. 50.5%, p=0.006) and had longer hospital stays (65% vs. 50.5%, p=0.023). They had more unplanned hospital visits (7.3% vs. 15.2%, p=0.048). However, no significant differences were observed on combined endpoint and on the other individual analysis of each outcome.</span></span></p> <p style="text-align:justify"><span style="font-family:Verdana,Geneva,sans-serif"><span style="font-size:12pt"><strong>Conclusion</strong>: Hyperuricemia in HF patients is associated with more systemic congestion, worse right ventricular function and lower LVEF reflecting a more severe disease phenotype. Hyperuricemia seems to be associated with worse outcomes, as reflected by a higher number of unplanned hospital visits. It remains to be determined whether hyperuricemia is merely a marker of disease severity or if it has a direct correlation with worse prognosis. </span></span></p> <p style="text-align:justify"> </p> <p> </p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site